Patents by Inventor Jindong Liang

Jindong Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRUG CONJUGATE OF ERIBULIN DERIVATIVE
    Publication number: 20240382607
    Abstract: A drug conjugate of an Eribulin derivative. Specifically, provided are an HER2 antibody conjugate that is formed by binding the Eribulin derivative to structural domain II of HER2, a preparation method therefor, and a pharmaceutical application thereof. The present invention further relates to a method for treating a cancer by means of administration of an antibody-drug conjugate, and a composition.
    Type: Application
    Filed: July 22, 2022
    Publication date: November 21, 2024
    Inventors: Xing SUN, Changyong YANG, Jindong LIANG, Cheng LIAO
  • ANTI-CD79B ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230405138
    Abstract: Provided are an anti-CD79B antibody-drug conjugate, and a preparation method therefor and pharmaceutical use thereof. In particular, provided are an antibody-drug conjugate (ADC) which comprises an anti-CD79B antibody conjugated with an MMAE or a derivative thereof, exatecan or a derivative thereof, or Eribulin or a derivative thereof, a pharmaceutical composition containing the ADC, and use thereof in preparation of a drug for treatment of a CD79B-mediated disease or disorder, especially use thereof in preparation of an anti-cancer drug.
    Type: Application
    Filed: July 27, 2021
    Publication date: December 21, 2023
    Inventors: Wenming REN, Jindong LIANG, Jianyan XU, Jian HUANG, Changyong YANG, Cheng LIAO
  • DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE
    Publication number: 20230144203
    Abstract: The present disclosure relates to a drug conjugate of an Eribulin derivative, a preparation method therefor and an application thereof in medicine. Specifically, provided is an antibody-drug conjugate, which contains an Eribulin derivative drug portion. The present disclosure further relates to a method for treating cancer by administering the antibody-drug conjugate provided herein.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 11, 2023
    Inventors: Jian HUANG, Lingjian ZHU, Xiuzhao YU, Bo ZHU, Wenming REN, Mi TANG, Xing SUN, Yang YANG, Jindong LIANG, Qiyue HU
  • LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
    Publication number: 20210353764
    Abstract: The present invention relates to a ligand-drug conjugate of an exatecan analogue, a preparation method therefor and an application thereof. Specifically, the present invention provides a ligand-drug conjugate having a structure shown in formula (-D), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in preparation of drugs for treating cancers by means of receptor regulation. The definition of each substituent in formula (-D) is the same as that in the description.
    Type: Application
    Filed: September 25, 2019
    Publication date: November 18, 2021
    Inventors: Jianyan XU, Ying ZHANG, Xiaofeng CAI, Bolei QU, Jindong LIANG, Lianshan ZHANG, Feng HE, Weikang TAO
  • Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
    Patent number: 10562977
    Abstract: Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: February 18, 2020
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yali Wang, Lianshan Zhang, Jindong Liang, Ang Li, Fanglong Yang
  • Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof
    Patent number: 10543284
    Abstract: Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: January 28, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jiajian Liu, Lianshan Zhang, Weikang Tao, Yayuan Fu, Ling Zhang, Dong Ma, Dongbing Cui, Yali Wang, Jianyan Xu, Jindong Liang, Ying Zhang, Guiyang Jiang, Junzhuan Qiu, Ziyong Sun, Jiping Zha, Jingping Wei
  • LIGAND-CYTOTOXIC DRUG CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF
    Publication number: 20180177890
    Abstract: Provide are ligand-cytotoxic drug conjugates with a general formula of PC-L-Dr, a preparation method thereof, and uses of the ligand-cytotoxic drug conjugate and pharmaceutical compositions containing the same in preparing drugs for treating cancers by means of receptor regulation.
    Type: Application
    Filed: January 26, 2016
    Publication date: June 28, 2018
    Inventors: Jianyan XU, Ying ZHANG, Bolei QU, Fuyao ZHANG, Xiuzhao YU, Jindong LIANG, Guiyang JIANG, Lianshan ZHANG, Ang LI, Yali WANG
  • ANTI-C-MET ANTIBODY AND ANTI-C-MET ANTIBODY-CYTOTOXIC DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF
    Publication number: 20180110875
    Abstract: Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.
    Type: Application
    Filed: April 7, 2016
    Publication date: April 26, 2018
    Inventors: Jiajian LIU, Lianshan ZHANG, Weikang TAO, Yayuan FU, Ling ZHANG, Dong MA, Dongbing CUI, Yali WANG, Jianyan XU, Jindong LIANG, Ying ZHANG, Guiyang JIANG, Junzhuan QIU, Ziyong SUN, Jiping ZHA, Jingping WEI
  • LIGAND-CYTOTOXIC DRUG CONJUGATE, PREPARATION METHOD THEREOF, AND USES THEREOF
    Publication number: 20170002090
    Abstract: Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.
    Type: Application
    Filed: January 22, 2015
    Publication date: January 5, 2017
    Applicants: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yali WANG, Lianshan ZHANG, Jindong LIANG, Ang LI, Fanglong YANG
  • Salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-trifluoromethyl-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine-1-carboxylic acid, preparation method and medical use thereof
    Patent number: 8518946
    Abstract: Pharmaceutically acceptable salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-formic acid, their preparation methods, compositions containing the said pharmaceutical salts and their use as medicaments, especially as dipeptidyl peptidase IV (DPP-IV) inhibitors are disclosed. Of the many acceptable salts, one example is the following.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: August 27, 2013
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Piaoyang Sun, Fanglong Yang, Jindong Liang, Guangyuan Shen, Yang Wang, Jiang Fan
  • TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE DERIVATIVES SALTS, PREPARATION METHODS AND MEDICINAL USE THEREOF
    Publication number: 20120065209
    Abstract: Pharmaceutically acceptable salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-formic acid, their preparation methods, compositions containing the said pharmaceutical salts and their use as medicaments, especially as dipeptidyl peptidase IV (DPP-IV) inhibitors are disclosed.
    Type: Application
    Filed: September 2, 2011
    Publication date: March 15, 2012
    Applicants: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Peng Cho Tang, Piaoyang Sun, Fanglong Yang, Jindong Liang, Guangyuan Shen, Yang Wang, Jiang Fan